Aankondiging • Mar 17
TegoScience Inc., Annual General Meeting, Mar 27, 2026 TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea New Risk • Nov 27
New major risk - Revenue and earnings growth Earnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m). New Risk • Jul 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m). Aankondiging • May 29
TegoScience Inc. announced that it has received KRW 27 billion in funding On May 27, 2025, TegoScience Inc. closed the transaction. New Risk • May 20
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m). Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years. Aankondiging • Mar 07
TegoScience Inc., Annual General Meeting, Mar 28, 2025 TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea New Risk • Jan 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m). Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years. New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m). Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years. New Risk • Nov 06
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m). Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years. New Risk • Aug 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m). New Risk • Jun 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m). New Risk • Mar 22
New major risk - Revenue and earnings growth Earnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). New Risk • Nov 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m). Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years. Is New 90 Day High Low • Feb 23
New 90-day low: ₩26,100 The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day high: ₩30,650 The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: ₩26,050 The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.